Source comparison
Topical vs Subcutaneous: Bioavailability Trade-Offs in Scar Treatment
Bioavailability differs dramatically between topical and subcutaneous peptide delivery, which shapes stacking strategy for BPC-157 and GHK-Cu scar minimization. BPC-157 has poor transdermal penetration. Its molecular weight (1419 Da) exceeds the 500 Da thresho
This comparison does not assign a generated winner or score.
- Bioavailability differs dramatically between topical and subcutaneous peptide delivery, which shapes stacking strategy for BPC-157 and GHK-Cu scar minimization. BPC-157 has poor transdermal penetration. Its molecular weight (1419 Da) exceeds the 500 Da threshold for passive diffusion across intact stratum corneum. A pharmacokinetic study in Drug Delivery measured less than 8% dermal uptake of topically applied BPC-157 even with penetration enhancers like DMSO. Subcutaneous injection delivers nearly 100% bioavailability at the target tissue, making subcutaneous the only viable route for BPC-157 in scar protocols.
- GHK-Cu behaves differently. Its smaller molecular weight (340 Da for the peptide, approximately 404 Da for the copper complex) allows modest transdermal penetration. Studies show 12–18% dermal uptake through intact skin, increasing to 35–40% through compromised barrier (wounds, abrasions, post-procedure skin). The copper ion acts as a penetration enhancer by disrupting lipid bilayer organization in the stratum corneum. Topical GHK-Cu formulations at 1–3% concentration achieve therapeutic dermal levels for collagen remodeling without systemic absorption, making topical the preferred route for cosmetic scar treatment where injection isn't practical.
- For stacking protocols targeting traumatic scars, surgical incisions, or burns: subcutaneous BPC-157 (250–500 mcg daily) combined with topical GHK-Cu (1–2% twice daily) provides optimal tissue-level concentrations without redundant administration. For atrophic scars (acne scars, stretch marks) where subcutaneous injection into scar tissue is impractical: GHK-Cu alone via microneedling delivery (0.5–1.5 mm depth) achieves dermal penetration comparable to subcutaneous injection, while BPC-157's poor transdermal uptake makes it ineffective in topical-only protocols. Real Peptides offers research-grade formulations of both peptides synthesized with verified amino acid sequencing. Precision that matters when bioavailability margins are this narrow.